These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28257284)

  • 1. Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
.
    Sreter KB; Barisic B; Popovic-Grle S
    Int J Clin Pharmacol Ther; 2017 May; 55(5):442-448. PubMed ID: 28257284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
    Vrkić Kirhmajer M; Macolić Šarinić V; Šimičević L; Ladić I; Putarek K; Banfić L; Božina N
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):509-518. PubMed ID: 29734517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
    Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
    Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics and drug toxicity.
    Nakamura Y
    N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
    Arrigoni E; Del Re M; Fidilio L; Fogli S; Danesi R; Di Paolo A
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome.
    Previsdomini M; Graziano E; Decosterd L; Courlet P; Perren A; Ceschi A
    Br J Clin Pharmacol; 2019 Jul; 85(7):1616-1618. PubMed ID: 31050036
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
    Corsini A; Ceska R
    Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
    Zhu T; Parker B; Wojtkowski T; Nishimura T; Garg JP; Han D; Fisniku O; Keirns J
    Clin Pharmacokinet; 2017 Jul; 56(7):747-757. PubMed ID: 27878567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin-induced rhabdomyolysis due to medication errors.
    Vodička M; Slanař O; Pisár M; Šálek T
    Ceska Slov Farm; 2020; 69(2):100-102. PubMed ID: 32545989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cluster of cases of high-dose rosuvastatin-associated rhabdomyolysis and recent reduction of rosuvastatin dose for Asians in other countries.
    Tse ML
    Hong Kong Med J; 2023 Oct; 29(5):474. PubMed ID: 37766464
    [No Abstract]   [Full Text] [Related]  

  • 13. The pharmacogenomics of statins.
    Gelissen IC; McLachlan AJ
    Pharmacol Res; 2014 Oct; 88():99-106. PubMed ID: 24365577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin-induced rhabdomyolysis: case report and call for proactive multifactorial risk assessment and preventive management of statin therapy in high-risk patients.
    Niedrig DF; Pyra M; Lussmann R; Serra A; Russmann S
    Eur J Hosp Pharm; 2024 Apr; 31(3):281-284. PubMed ID: 37451842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein-mediated drug interaction?
    Lehtisalo M; Kiander W; Filppula AM; Deng F; Kidron H; Korhonen M; Sinkko J; Koivula K; Niemi M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2309-2315. PubMed ID: 36740817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of pharmacogenetic variation on the effects of statins.
    Maggo SD; Kennedy MA; Clark DW
    Drug Saf; 2011 Jan; 34(1):1-19. PubMed ID: 21142270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyolysis associated with simvastatin-nefazodone therapy.
    Skrabal MZ; Stading JA; Monaghan MS
    South Med J; 2003 Oct; 96(10):1034-5. PubMed ID: 14570351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics and adverse drug reactions: the case of statins.
    Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
    Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection-Induced Rhabdomyolysis in an Elderly Patient on Stable Rosuvastatin Therapy: A Case Report and Review of the Literature.
    Guo D; Meng Z; He F; Liu G; Huang X
    Am J Ther; 2022 Nov-Dec 01; 29(6):e657-e661. PubMed ID: 33443867
    [No Abstract]   [Full Text] [Related]  

  • 20. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
    Mitka M
    JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.